One Inhaler for Both Jobs: Moving a 27-Year-Old Line Cook From a Skipped Daily Steroid and Four Albuterol Days a Week to Budesonide-Formoterol Maintenance and Reliever Therapy
[Student Name]
University of Phoenix
NRP/507: Advanced Pharmacology
Week 5 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Mr. J., a 27-year-old line cook, comes to our clinic for a refill of albuterol. He uses it about four days a week, usually during evening shifts near the fryers, and wakes at night coughing about twice a month. He has a prescription for fluticasone 110 mcg, two puffs twice daily, but admits he uses it "when things get bad," perhaps a few days a month. He had one course of oral prednisone from urgent care six months ago. His spirometry today shows an FEV1 of 78% of predicted. This paper explains how I assess his asthma and why I change his regimen rather than adding another inhaler.
Assessing Control
The national asthma guideline classifies control by impairment and risk (Cloutier et al., 2020). Symptoms more than two days a week, reliever use more than two days a week and nighttime awakening one to three times a month indicate asthma that is not well controlled. His oral steroid course in the past year adds risk. Mr. J.'s asthma is therefore not well controlled, and the guideline calls for stepping up care after checking adherence, technique and triggers.
Why He Is Not Controlled
The problem is not the strength of his controller; it is that he rarely takes it. Like many young adults, he feels well most days and sees no reason for a daily medicine. He trusts albuterol because it works in minutes. A second daily inhaler added on top of the first would likely go unused as well. A regimen that depends on a daily habit the patient does not have is not a stronger regimen, only a longer prescription.
What the Guideline Now Recommends
The 2020 focused update to the national asthma guideline recommended single maintenance and reliever therapy with an inhaled corticosteroid and formoterol as the preferred treatment at steps 3 and 4 for individuals 12 years and older (Cloutier et al., 2020). In this approach, one inhaler is used daily and also for symptoms, so each reliever dose adds inhaled steroid at the time inflammation is flaring.
The Evidence
Pooling 16 randomized trials with 22,748 participants, Sobieraj et al. (2018) found that among patients 12 years and older, single maintenance and reliever therapy reduced the risk of asthma exacerbations compared with the same dose of inhaled corticosteroid and long-acting beta-agonist as controller (risk ratio 0.68) and compared with a higher controller dose (risk ratio 0.77), with short-acting beta-agonists as reliever in the comparison groups. In mild asthma, a trial of 3,849 patients found that as-needed budesonide-formoterol reduced severe exacerbations to a rate similar to daily budesonide and much lower than as-needed terbutaline, with a median daily steroid dose about 17% of the daily budesonide group, although symptom control was not as good as daily budesonide (O'Byrne et al., 2018). Together, these results suggest that tying steroid doses to reliever use protects against exacerbations even when daily adherence is imperfect.
The Regimen
I prescribe budesonide-formoterol 80/4.5 mcg, one to two inhalations twice daily for maintenance and one inhalation as needed for symptoms, which fits the low-dose step 3 regimen for his age (Cloutier et al., 2020). The total should not exceed 12 inhalations in a day; if he needs more, he should seek care. I stop the fluticasone and the albuterol, explaining that the new inhaler replaces both, so he does not use three inhalers and confuse their roles.
Mechanism
Budesonide reduces airway inflammation by acting on glucocorticoid receptors, decreasing inflammatory cell activity and airway hyperresponsiveness over time. Formoterol stimulates beta-2 receptors for about half a day yet begins acting quickly, relaxing airway smooth muscle within minutes and lasting about 12 hours. Formoterol should never be used without an inhaled steroid in asthma, and the combination inhaler ensures it is not.
Checking Technique
Poor technique defeats any inhaler. I ask Mr. J. to demonstrate the metered-dose inhaler and find that he inhales too fast and does not hold his breath. I teach a slow, deep breath with a 10-second breath-hold and provide a spacer, then watch him demonstrate it back. He will bring the inhaler to each visit for a check.
Triggers at Work
Fumes from frying and the heat and steam of the kitchen are common triggers. I ask whether his employer has exhaust hoods working over the fryers and suggest he speak with his manager about ventilation. I also screen for allergic rhinitis, which he has, and add a nasal steroid, since treating the nose can improve asthma control. He smokes two or three cigarettes a day; I discuss quitting and offer nicotine replacement, since smoking reduces the response to inhaled steroids.
Written Action Plan
Mr. J. receives a written plan that says what to take every day, what to do when symptoms increase, when to call the clinic and when to go to an emergency department, including if he needs more than 12 inhalations in a day, has trouble speaking or his lips turn blue. The plan is written for the new regimen, which differs from older action plans built around albuterol.
Adverse Effects
He may notice hoarseness or oral thrush from the steroid; rinsing his mouth after use reduces the risk. Formoterol may cause a tremor or a fast heartbeat at higher doses. These are uncommon at his dose.
Why Not Simply Add a Long-Acting Drug to His Fluticasone?
A fixed-dose inhaled steroid and salmeterol twice daily, with albuterol for relief, is the traditional step 3 alternative. For Mr. J., it would repeat the problem: a daily inhaler he does not use and a reliever that treats the symptom but not the inflammation. The meta-analysis compared exactly this approach with single maintenance and reliever therapy and favored the single inhaler for exacerbations.
Cost and Coverage
Budesonide-formoterol is more expensive than generic albuterol. His insurance covers it with a copay, and I check the pharmacy benefit before he leaves. If cost becomes a barrier, generic versions or manufacturer assistance may help; if not, a daily inhaled steroid with a separate reliever remains an option, though less suited to his habits.
Follow-Up
I will see him in four weeks to review symptoms, reliever use, night waking, technique and any side effects, and repeat spirometry in three months. If his asthma is well controlled for at least three months, the guideline allows stepping down. If it is still not controlled, I will increase the maintenance dose to the medium-dose step 4 level (Cloutier et al., 2020).
Conclusion
Mr. J.'s asthma was uncontrolled because he rarely took his daily steroid and relied on albuterol. Single maintenance and reliever therapy with budesonide-formoterol, the preferred approach at his step for patients 12 years and older, delivers steroid every time he reaches for relief. Trial evidence shows fewer exacerbations with this approach, and teaching, technique checks and trigger control give it the best chance to work.
References
Cloutier, M. M., Baptist, A. P., Blake, K. V., Brooks, E. G., Bryant-Stephens, T., DiMango, E., Dixon, A. E., Elward, K. S., Hartert, T., Krishnan, J. A., Lemanske, R. F., Jr., Ouellette, D. R., Pace, W. D., Schatz, M., Skolnik, N. S., Stout, J. W., Teach, S. J., Umscheid, C. A., & Walsh, C. G. (2020). 2020 focused updates to the asthma management guidelines: A report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Journal of Allergy and Clinical Immunology, 146(6), 1217-1270. https://doi.org/10.1016/j.jaci.2020.10.003
O'Byrne, P. M., FitzGerald, J. M., Bateman, E. D., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Ivanov, S., & Reddel, H. K. (2018). Inhaled combined budesonide-formoterol as needed in mild asthma. New England Journal of Medicine, 378(20), 1865-1876. https://doi.org/10.1056/NEJMoa1715274
Sobieraj, D. M., Weeda, E. R., Nguyen, E., Coleman, C. I., White, C. M., Lazarus, S. C., Blake, K. V., Lang, J. E., & Baker, W. L. (2018). Association of inhaled corticosteroids and long-acting beta-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: A systematic review and meta-analysis. JAMA, 319(14), 1485-1496. https://doi.org/10.1001/jama.2018.2769
How this NRP 507 Week 5 example is structured
The NRP/507 Week 5 work usually presents a respiratory case, often asthma or chronic obstructive pulmonary disease, and asks for a drug plan grounded in current guidelines. This paper assesses control and step, identifies the real reason treatment is failing, chooses a regimen matched to how the patient actually uses inhalers and defines what will show that it works. Students search this week as NRP 507 Week 5, NRP507 Wk 5 or NRP/507 Wk 5; all three are the same assignment.
NRP/507 Week 5 questions, answered
What does NRP/507 Week 5 usually ask for?
Many sections present an asthma or COPD case and ask students to classify severity or control, choose drug therapy by guideline step and plan monitoring and teaching.
What is single maintenance and reliever therapy?
A regimen using one inhaler containing an inhaled corticosteroid and formoterol both daily and as needed for symptoms, so every reliever dose also delivers anti-inflammatory medicine.
Why formoterol and not salmeterol for SMART?
Formoterol starts working within minutes, so it can serve as a reliever. Salmeterol has a slower onset and is not used as needed.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.